Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
1 - 10 of 63
- Understanding and targeting melanoma mesenchymal-like cells to improve response to immunotherapyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Deciphering molecular mechanisms and intercellular communication networks underlying the emergence of the metastasis-initiating melanoma cellFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Spatio-temporal dissection of inter-cellular melanoma communication networks that contribute to resistance to immunotherapy.From1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Empowering precision medicine in melanoma: Exploring the potential of an implantable microdevice for large-scale drug screening in vivoFrom12 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Microfluidic tools to study single-cell responses and cell-cell communication in cancer applicationsFrom15 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of universal biomarkers of metastatic melanoma in CTCsFrom30 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Detection and prevention of early metastatic dissemination of melanomaFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Dissecting the cellular and molecular interaction networks that promote melanoma stemness at the perivascular niche.From1 Oct 2022 → TodayFunding: FWO senior postdoctoral fellowship
- Circulating tumor cells as a target of anti-metastatic treatment in melanoma.From1 Sep 2022 → TodayFunding: FWO Strategic Basic Research Grant
Publications
41 - 50 of 153
- Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis(2021)
Authors: Chris Marine
Pages: 203 - 218 - Non-genetic mechanisms of therapeutic resistance in cancer(2020)
Authors: Chris Marine
Pages: 743 - 756 - Cross-species analysis of enhancer logic using deep learning(2020)
Authors: Liesbeth Minnoye, Ibrahim Ihsan Taskiran, David Mauduit, Linde Van Aerschot, Panagiotis Karras, Chris Marine, Jasper Wouters, Stein Aerts
- Unravelling enhancer landscapes in melanoma(2020)
Authors: Liesbeth Minnoye, Stein Aerts, Jasper Wouters, Chris Marine
- LifeTime and improving European healthcare through cell-based interceptive medicine(2020)
Authors: Stein Aerts, Bart De Strooper, Chris Marine, Thierry Voet
Pages: 377 - 386 - A Tale of NEAT1 Tails(2020)
Authors: Jasmine Barra, Chris Marine, Eleonora Leucci
- Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma(2020)
Authors: Jasper Wouters, Liesbeth Minnoye, Katina Spanier, David Mauduit, Kristofer Davie, Michael Dewaele, Dennis Pedri, Frederik Ceyssens, Chris Marine, Stein Aerts
Pages: 986 - + - The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype(2020)
Authors: Jasper Wouters, David Nittner, Danny Huylebroeck, Joost van den Oord, Chris Marine
Pages: 2983 - 2995 - Integrator restrains paraspeckles assembly by promoting isoform switching of the lncRNA NEAT1(2020)
Authors: Jasmine Barra, Eleonora Leucci, Chris Marine
- Disseminated Melanoma Cells Transdifferentiate into Endothelial Cells in Intravascular Niches at Metastatic Sites(2020)
Authors: Panagiotis Karras, Joost van den Oord, Chris Marine
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)